Enterprise Value
191.5M
Cash
105.6M
Avg Qtr Burn
-29.12M
Short % of Float
10.99%
Insider Ownership
0.84%
Institutional Own.
17.59%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INO-3107 Details Respiratory conditions, Lung disease, Recurrent respiratory papillomatosis | BLA Submission | |
VGX-3100 Details Anal cancer, Cancer, High-grade squamous intraepithelial lesion | Phase 3 Data readout | |
INO-5401 + Libtayo Details Glioblastoma, Solid tumor/s | Phase 2 Update | |
Phase 1b Update | ||
INO-5151 Details Arthritis, Cancer, Prostate cancer | Failed Discontinued | |
PENNVAX-GP Details Human immunodeficiency virus, Sexually transmitted infections | Failed Discontinued | |
MEDI0457 Details Cancer, Anal cancer, Cervical cancer | Failed Discontinued | |
MEDI0457 Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued | |
INO-4800 Details Infectious disease, COVID-19 | Failed Discontinued | |
INO-4700 / GLS-5300 Details Infectious disease, Middle east respiratory syndrome | Failed Discontinued |